Dermata Therapeutics shares surged 22% premarket after announcing a private placement to issue about 2.02 million shares priced at $2.04 per unit, with attached warrants. Proceeds will fund general corporate needs, including consumer research and the rollout of its upcoming over-the-counter acne kit and refreshed skincare brand.